Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | CFD | P00746 | 1/20 | 0.42 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13640205 | 0.87 | ADRA1A (0.48) | ALDH1A1RAB9ANPC1SMN1; SMN2LMNA | |
| SCHEMBL1485664 | 0.82 | CYP3A4 (0.44) | ALDH1A1RAB9ATSHRKDM4EGAA | |
| SCHEMBL10438024 | 0.81 | ALDH1A1 (0.46) | ALDH1A1RAB9ANPC1SMN1; SMN2LMNA | |
| SCHEMBL11055322 | 0.80 | ELANE (0.49) | ALDH1A1RAB9ANPC1SMN1; SMN2LMNA | |
| SCHEMBL12476289 | 0.79 | ACHE (0.54) | ALDH1A1KDM4EGAAACHE | |
| SCHEMBL8350024 | 0.79 | TSHR (0.60) | ALDH1A1RAB9ANPC1SMN1; SMN2LMNA | |
| SCHEMBL29380051 | 0.79 | LMNA (0.57) | LMNA | |
| SCHEMBL250091 | 0.79 | LMNA (0.57) | LMNA | |
| SCHEMBL1799618 | 0.77 | LMNA (0.52) | ALDH1A1RAB9ANPC1SMN1; SMN2LMNA | |
| SCHEMBL8324534 | 0.76 | PTGS2 (0.53) | ALDH1A1LMNATSHRKDM4EACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10675353-B2 | Pegylated carfilzomib compounds | AMGEN INC. (US) | 2020-06-09 | — | — | US | disclosed |
| US-20200069808-A1 | PEGYLATED CARFILZOMIB COMPOUNDS | AMGEN INC. | 2020-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10675353-B2 | Pegylated carfilzomib compounds | FCGRT, EPOR, MCL1 | ALDH1A1 1647/4885RAB9A 655/4885NPC1 574/4885 |
| US-20200069808-A1 | PEGYLATED CARFILZOMIB COMPOUNDS | FCGRT, EPOR, MCL1 | ALDH1A1 1647/4885RAB9A 655/4885NPC1 574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.